ANI Pharmaceuticals (ANIP) is intensifying its focus on the Rare Disease franchise, primarily driving growth through Purified Cortrophin Gel, with a specific commercial expansion into acute gouty arthritis flares. This move leverages a largely untapped patient population, with the company assembling a dedicated sales force of approximately 90 personnel to support this initiative. The initial marketing efforts have already contributed to a 12% year-over-year increase in selling, general, and administrative expenses, reaching $71.4 million in Q1 2026.
In addition to acute gout, ANI aims to recover momentum in its retina franchise, which includes the unified Iluvien brand, projected to generate $78-$83 million in sales for 2026. Investors can track performance through specific milestones, including a licensing agreement with Harmony Biosciences that provided a $15 million upfront payment and anticipates an additional $10 million in development milestones in mid-2026.
ANI faces competition primarily from Acthar Gel by Keenova Therapeutics, impacting growth in ACTH therapies. Meanwhile, the combination of its generics pipeline, with 10-15 planned launches in 2026, and progress in the retina sector highlights ANI’s aim to diversify revenue sources and drive shareholder value.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
